Sun Pharma Advanced Research Company Ltd.

NSE: SPARC | BSE: 532872

Download real time

161.21 1.87 (1.17%)

33.11% Fall from 52W High

578.0K NSE+BSE Volume

NSE 14 Jul, 2025 3:31 PM (IST)

5,231.6

Market Cap

Above industry Median

1.3

Beta 1Year

Very High Volatility

Sun Pharma Advanced Research Company Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SPARC, BSE:532872 Sun Pharma Advanced Research Company Ltd.

Search Inside the pdf :

Sun Pharma Advanced Research Company Ltd.

10 Dec 2019

161.21

1.17%

Event Update

Not Rated: Sun Pharma Advanced Resear...

Prabhudas Lilladhar

Sun Pharma Advanced Research (SPARC) received a resolution for Abraxane as Abraxis Biosciences LCC withdrew its infringement claims yesterday in the US District Court of New Jersey. Earlier, Abraxis filed a complaint in the court that the NDA (505b2) of SPARC (Abraxane) has breached patent and sued them for its filing of Taclantis (Paclitaxel Injection concentrate for Suspension) in the District Court. While the event is a positive development in February FY20E (filed with USFDA in June2019). SPARC will have three potential annual sales of US$25-30m. Not Rated SPARC evaluating marketing options...

Sun Pharma Advanced Research Company Ltd. is trading below its 30 day SMA of 161.4

Sun Pharma Advanced Research Company Ltd.

11 Jun 2015

161.21

1.17%

SPARC Investor Presentation & Conference Call Update (Jun 11, 2015)

Sun Pharma Advanced Resear...

Karvy

Four New Products Added to Pipeline; Xelpros NDA Submission CompletedSPARC replied to the Complete Response Letter (CRL) from USFDA for Xelpros (Latanoprost BAK-Free) in April 2015, this completes the full submission of NDA for Xelpros.

Number of FII/FPI investors decreased from 90 to 54 in Mar 2025 qtr

Sun Pharma Advanced Research Company Ltd.

11 Jun 2015

161.21

1.17%

SPARC-Event Update

Sun Pharma Advanced Resear...

Reliance Securities

Sun has discontinued certain programs after commercial assessment of the molecules and found them unviable on economic and commercial standpoints. These include candidates such as Venlafexine ER 300mg, Sun...

Sun Pharma Advanced Research Company Ltd. has lost -31.66% in the last 1 Year

Sun Pharma Advanced Research Company Ltd.

03 Mar 2015

161.21

1.17%

Sun Pharma Advanced Research Company Ltd. (SPARC) - Initiating Note (Mar 03, 2015)

Sun Pharma Advanced Resear...

Karvy

Innovating New Drug Delivery Systems and New Drugs: Sun Pharma Advanced Research Company (SPARC) is primarily involved in new drug discovery, research and development, unlike other Indian pharma firms that mainly manufacture generic medicines. SPARC has been granted 20 US patents for various inventions. The company has 11 novel products in pipeline at various development stages for launch in US. Some products have been launched in India.

Sun Pharma Advanced Research Company Ltd. is trading below its 30 day SMA of 161.4

Is Sun Pharma Advanced Research Company Ltd. worth buying?

207 Votes:

Buy 71.98%

Sell 19.81%

Hold 8.21%